What is InoCardia?
InoCardia is dedicated to providing superior, predictive cardiac contractility data for early drug discovery. The organization utilizes a unique approach by manipulating pre- and after-load to directly measure microscopic changes in myocyte contraction force. This methodology yields a comprehensive suite of cardiac contractility data from a single myocyte, notably including the Work Loop model. The company has successfully completed a 3-year NC3R/InnovateUK project aimed at miniaturizing its Work Loop platform, a development that has paved the way for its groundbreaking cardiac contractome AI concept, supported by EIT Digital.
How much funding has InoCardia raised?
InoCardia has raised a total of $452K across 1 funding round:
Private Equity
$452K
Private Equity (2015): $452K with participation from Mercia Fund Management
Key Investors in InoCardia
Mercia Fund Management
Mercia Fund Management is a UK-based entity operating within the Venture Capital & Private Equity industry, known for its investments in innovative companies.
What's next for InoCardia?
With the recent influx of capital, InoCardia is strategically positioned for its next phase of expansion. The large-scale, late-stage funding suggests a focus on scaling operations, enhancing its AI-driven cardiac contractome platform, and potentially broadening its market reach within the pharmaceutical and biotechnology sectors. This investment will likely fuel further research and development, solidifying InoCardia's role as a key player in improving the efficiency and accuracy of early-stage drug discovery through advanced cardiac contractility analysis.
See full InoCardia company page
